Interleukin-17-mediated signaling pathway

Across TCGA pan-cancer cohorts, RNA activity of the Interleukin-17-mediated signaling pathway pathway differs between tumor and matched normal tissue in 11 of the 18 cancer types tested.

The strongest signal is observed in lung adenocarcinoma (LUAD), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as KICH and THCA, show the opposite pattern, with lower activity in tumor tissue.

LUAD, KICH, and THCA show the most reproducible tumor–normal differences in pathway activity.

Tumor vs normal pathway activity by lineage

Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log₂ scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.

Lineage	Gender	Stage	Activity change	p	Sampling consensus
LUAD	Male	All	+0.059	<.001	7	view →
KICH	Male	All	−0.060	<.001	6	view →
THCA	All	All	−0.030	<.001	6	view →
BRCA	All	All	+0.029	<.001	6	view →
STAD	All	All	+0.070	<.001	4	view →
HNSC	Male	II,III,IV	+0.037	.004	4	view →
LUSC	All	All	+0.032	<.001	4	view →
CHOL	All	All	+0.100	<.001	3	view →
BLCA	Female	All	+0.052	.034	3	view →
PRAD	All	All	−0.029	<.001	2	view →
KIRC	All	All	+0.014	.024	2	view →

Pink = more active in tumor, green = less active in tumor. Showing the 11 strongest of 11 lineages.

GO:0097400–LUAD

Open the LUAD breakdown →